Drug Index


Mechanism :

Carvedilol is a cardiovascular agent for the treatment of CHF that combines beta-adrenoceptor blockade and vasodilation in a single racemic mixture. Nonselective beta-adrenoceptor blocking activity is present in the S(-) enantiomer and alpha 1-adrenoceptor blocking activity is present at equal potency in both the R(+) and S(-) enantiomers. Carvedilol has no intrinsic sympathomimetic activity. Its action on beta-receptors is 10 times stronger than on alpha 1-receptors.

Indication :

  • Congestive heart failure
  • Left ventricular dysfunction following myocardial infarction
  • Hypertension

Contraindications :

Contraindicated in patients with bronchial asthma or related bronchospastic conditions, second- or third-degree AV block, sick sinus syndrome or severe bradycardia (unless a permanent pacemaker is in place), or in patients with cardiogenic shock or who have decompensated heart failure requiring the use of intravenous inotropic therapy. Such patients should first be weaned from intravenous therapy before initiating carvedilol.

Use in patients with clinically manifest hepatic impairment is not recommended.

Contraindicated in patients with hypersensitivity to any component of the product.

Dosing :

Start with initial doses of 0.025 mg/kg/dose BDS orally, increased as tolerated, by doubling the dose every 2 weeks. Usual dose is 0.2-2 mg/kg/day PO in 2-3 divided doses. Max: 2 mg/kg/day or 50 mg/day.

Adverse Effect :

Cardiac failure, syncope, bradycardia, myocardial infarction, acute renal failure, AV block, worsening renal function, sleep disorder, aggravated depression, impaired concentration, abnormal thinking, emotional labiality, asthma, decreased libido in males, pruritus, rash, tinnitus, increased micturition frequency, dry mouth, increased sweating, diabetes mellitus.

Interaction :

Antihypertensive Agents: When administered concomitantly with other drugs that are antihypertensive in action or have hypotension as part of their adverse effect profile, carvedilol may have additive effects to excessively lower blood pressure.
Catecholamine-Depleting Agents: Patients taking both agents with b-blocking properties and a drug that can deplete catecholamines (e.g., reserpine and MAO inhibitors) should be observed closely for evidence of hypotension and/or marked bradycardia.
Antiarrhythmics and Calcium Channel Blockers: Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when carvedilol is coadministered with antiarrhythmic agents or calcium channel blockers such as diltiazem and verapamil that can slow cardiac conduction.
Digoxin: Following concomitant administration of carvedilol and digoxin, peak concentration of digoxin increased by approximately 30% and steady-state trough concentrations of digoxin were increased by about 15%. Both digoxin and carvedilol slow AV conduction. Therefore, increased monitoring of digoxin levels is recommended when initiating, adjusting or discontinuing carvedilol.
Clonidine: Concomitant administration of clonidine with agents with beta-blocking properties may potentiate blood pressure and heart rate lowering effects. When concomitant treatment with agents with beta-blocking properties and clonidine is to be terminated, the beta-blocking agent should be discontinued first. Clonidine therapy can then be discontinued several days later by gradually decreasing the dosage.
Inducers and Inhibitors of Cytochrome P450: Since carvedilol undergoes substantial oxidative metabolism, care may be required in patients receiving inducers or inhibitors of cytochrome P450, as plasma concentrations may be altered.

Renal Dose :

Dose in Renal Impairment GFR (mL/min)
20-50Dose as in normal renal function
10-20Dose as in normal renal function
<10Dose as in normal renal function

Dose in Patients undergoing Renal Replacement Therapies
CAPDUnlikely dialysability. Dose as in normal renal function. Start with low doses and titrate according to response
HDNot dialysed. Dose as in normal renal function. Start with low doses and titrate according to response
HDF/High fluxUnknown dialysability. Dose as in normal renal function. Start with low doses and titrate according to response
CAV/VVHDUnlikely dialysability. Dose as in normal renal function. Start with low doses and titrate according to response

Hepatic Dose :

Contraindicated in patients with severe hepatic impairment.
02/18/2024 17:35:52 Carvedilol
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0